Market leadership in October shifted heavily toward heavyweights in banking, pharmaceuticals, and technology, leaving broader indices subdued as midcap and smallcap benchmarks dropped more than 3.7%. Technical strength in the software sector is supported by reclaimed moving averages alongside a bullish monthly relative strength index crossover. Meanwhile, individual equities show sharp divergence, with chemical names breaking out to multi-thousand rupee targets while consumer platform stocks face severe overhead resistance.
Key points
Technical momentum and global asset reallocation from semiconductor equities point toward…: Technical momentum and global asset reallocation from semiconductor equities point toward an intermediate upside objective of 35,000 for technology shares.
Swiggy faces technical downside risk toward Rs 155 if the price slips beneath its vital R…: Swiggy faces technical downside risk toward Rs 155 if the price slips beneath its vital Rs 170 support boundary.
Sustained trading above Rs 3,700 positions Acutaas Chemicals to challenge medium-term tar…: Sustained trading above Rs 3,700 positions Acutaas Chemicals to challenge medium-term targets spanning from Rs 4,350 to Rs 4,700.
Sources checked by our analysis pipeline: 1
Edited excerpts from a chat:
Nifty gained around 2% in October, but the Nifty 500, midcaps and smallcaps have remained under pressure. Is this a genuine market recovery or merely a narrow largecap-led bounce?
The divergence in market performance suggests that the ongoing recovery remains selective and largely driven by heavyweight large-cap stocks, rather than signalling a broad-based market turnaround.
The October recovery was largely driven by a handful of heavyweight large-cap stocks rather than broad-based market participation. Nifty gained 1.91% during the month, whereas the Nifty Midcap 150 and Nifty Smallcap 100 indices declined 3.75% and 4.06%, respectively. Stocks from sectors such as IT, pharmaceuticals and banking contributed significantly to the Nifty's outperformance, particularly during the last week of October. This was also supported by the global rotation away from AI and semiconductor stocks amid profit booking.
Going ahead, continued profit booking in global AI-related stocks could potentially benefit Indian IT companies. However, the divergence in market performance suggests that this is still a selective, largecap-led recovery rather than a broad-based market turnaround.
A sharp market downturn following gold's worst-ever October performance has triggered heavy selling across both domestic and international precious metals markets. Heightened expectations of a December Federal Reserve rate hike and sticky inflation figures have severely undermined investor appetite for non-yielding assets. Consequently, prices are extending their decline toward levels not seen since late 2025 as macroeconomic pressures mount.
Utssav CZ Gold Jewels is rewarding investors by funding a capital expansion through its securities premium, free reserves, and retained earnings. This corporate action will effectively double the jewellery manufacturer's existing paid-up capital and outstanding shares once regulatory clearances are secured. Despite recent technical pullbacks, the move reflects substantial balance sheet strength built during an aggressive multi-fold market rally this year.
Robust economic activity and a sharp surge in imports provided a significant boost to India's fiscal receipts during the month. Net revenue experienced an even stronger expansion after accounting for taxpayer refunds, indicating healthy underlying consumption trends. Major state economies across the nation maintained solid growth trajectories, with smaller regions posting substantial momentum in their tax intake.